Changes

* “Medication "Medication for men plagued by hair loss has become a topic of interest in Japan since a drug company began marketing it at the end of last year." March 5th, 2006 – [http://stophair.setupmyblog.com/?p=55Source] * “An "An increasing number of companies are apparently turning the Chinese fear of a bald spot into big bucks with some doing so well they are branching out into other countries.” " February 16, 2006 – [http://stophair.setupmyblog.com/Source]* "There is something in the air, or should we say in the hair, these days. Scientific research into hair loss remedies has never been more active or more exciting." June 7, 2006 - [http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/06-07-2005/0003821470&EDATE= Source]<br><br><br>

=== Hair Basics basics ===* Hair is a complex and delicate part of the body .* Keeping it healthy and beautiful is a challenge.* Hair grows everywhere on the body with the exception of lips, eyelids, palms of the hands and soles of the feet.* Hair is basically a form of skin. * Hair is made up of a protein called keratin.* Each shaft of hair is made of two or three inter-twined layers of keratin which grow from a follicle beneath the skin. * Hair Structure - [http://www.pg.com/science/haircare/hair_twh_12.htm Source]* Hair Cycle - [http://www.follicle.com/hair-structure-life-cycle.html Source]

* Keeping it healthy and beautiful is a challenge[[Image:Hairbasics.jpg|thumb|center|500px400px|Structure of Hair root and Hair bulb]]

=== Reasons for Hair What causes hair loss ? === * Decrease in growth of hair * Increase in shedding of hair * Breakage of hair * Conversion of thick terminal hairs to thin vellus hairs [[Image:Facts.jpg|thumb|right|400px250px|Survey results from Japan]]Both men and women lose hair for similar reasons. Hair loss in men is often more dramatic, and follows a specific pattern of loss , one of which has been termed “Male Pattern Baldness” (Baldness" or "Androgenetic Alopecia)".

* Hormonal effect === Types of androgen alopecia===

* Reduction Alopecia Areata (AA): Hair loss occurring in patches anywhere on the body.* Alopecia Totalis (AT): Total loss of blood circulation around the hair follicleon the scalp.* Alopecia Universalis (AU): Total loss of all hair on the body.* Alopecia Barbae: Loss of facial hair (for a man) especially in the beard area.* Alopecia Mucinosa: A type of alopecia which results in scaley patches.* Androgenetic Alopecia (AGA): Also known as male pattern baldness. It is a thinning of the hair to an almost transparent state, in both men or women. It is thought to be a hereditary form of hair loss.* Traction Alopecia: Traction alopecia is usually due to excessive pulling or tension on hair shafts as a result of certain hair styles. It is seen more often in women, particularly those of East Indian and Afro-Caribbean origin. Hair loss depends on the way the hair is being pulled. Prolonged traction alopecia can stop new hair follicles from developing and leads to permanent hair loss.* Anagen Effluvium: This hair loss is generally caused by chemicals such as those used to treat cancer. Initially it causes patchy hair loss, which often then leads to total hair loss. The good news is that when you stop using these chemicals the hair normally grows back (usually about 6 months later). Other drugs also can cause hair loss. Many medicines used to treat even common diseases can cause hair loss.* Scarring Alopecia: A form of alopecia which leaves scarring on the area of hair loss.* Telogen Effluvium: A form of hair loss where more than normal numbers of hair fall out. There is a general 'thinning' of the hair. Unlike some other hair and scalp conditions, it is temporary and the hair growth usually recovers. ([http://www.alopeciaonline.org.uk/about/types.asp Source])

== Goals IP activity over the years ==The graph indicates:* Number of patents filed every 5 years (except for first 7 years).* First solution proposed in 1973* Filing trend indicates steep rise in activity recently.[[Image:Year1.jpg|thumb|center|400px|IP Activity over years]]

* Summarize IP activity over the years== Major players ==* Identify major [[Image:players.jpg|thumb|left|500px|Assignees with more than 20 patents ]]* Conduct patent analysisa) Compositionb) Naturec) Action[[Image:players1.jpg|thumb|center|500px|Assignees with fewer than 20 patents ]]<br>

* '''Alopecia occurs, due toActive assignees''' Assignees currently active with more than 5 patents to their credit during 2000-2005. * Warner with 9 patents,* Bristol with 6 and* Abbott with 5.

== Approach Interactive Taxonomy ==''Use the mouse(click and drag/scroll up or down/click on nodes) to explore nodes in the detailed taxonomy'' <br>''Click on the red arrow on the side of a node name to view the content for that particular node in the dashboard''

Broad search conducted on hair loss patents<mm>[[Map12.mm]]</mm>

Patents selected randomly for analysis* Anti-androgens (Finasteride) [http://www.emedicine.com/DERM/topic21.htm source]* Vasodilators (Minoxidil) [http://www.emedicine.com/DERM/topic21.htm source]* Double action (Anti-androgen + Vasodilator)* Hair matrix cells activator

Composition of treatment for causes identified and categorized as follows{|border="1" cellpadding="2", style="#008080" align="center"|- style="font-weight:bold" valign="top"! Cause !! Treatment approach !! Pathways affected

* Anti|- valign="top"| Hormonal effect of androgen* Minoxidil* Double action (|| Anti-androgen + Mindoxidil)* Hair matrix cells activator* Sebum production inhibitorandrogens || Testosterone pathway

|- valign== IP activity over years =="top"The graph indicates:.[[Image:Activity.jpg|thumbDeactivation of hair matrix cells |right|400pxHair matrix cells activator|IP Activity over years]]* Number of patents filed every 5 years (except for first 7 years).Wnt pathway* First solution proposed in 1973STAT pathway* Filing trend indicates steep rise in activity recently.TGF beta/BMP Pathway* FGF Pathway* MAPK Pathway* NOTCH Pathway* Hedgehog Pathway|}

== Major Players = Anti-androgens ===* '''Assignees with more than 20 patents Anti-androgens are used in hormone therapy.* Anti-androgens are designed to their creditaffect the hormones made in the adrenal glands. They don'''[[Image:playerst stop the hormones from being made, but they stop them from having an effect leading to hair loss.jpg|thumb|center|700px|Assignees with more than 20 patents ]]

* '''Assignees with less than 20 patents to their creditWhat causes hair loss?'''[[Image:players1* Testosterone is reduced to its active metabolite, Dihydrotestosterone (DHT) by the enzyme 5 alpha reductase.* DHT attaches to androgen receptor sites at the hair follicle. * DHT causes gradual miniaturization of the follicle, which eventually results in hair loss.jpg|thumb|center|700px|Assignees with less than 20 patents ]]

* '''Active AssigneesHow do anti-androgens treat hair loss?'''Assignees currently active * Anti-androgens compete with more than 5 patents DHT to bind to their credit during 2000-2005, among themfollowing are the leaders androgen receptor.* Upon binding of 2005anti-androgen in place of DHT, follicle miniaturization is lowered and hair loss prevented.

ABBOTT with 5[[Image:Andogen1.jpg|thumb|center|500px|Functions of Anti-androgen]]

{| border="1" cellpadding= Anti-androgens "0", style="#008080"!width="120" bgcolor=DodgerBlue|'''Pat/Pub#'''!width="100" bgcolor=DodgerBlue|'''Nature'''!width="450" bgcolor=DodgerBlue|'''Composition''' !width="400" bgcolor=DodgerBlue|'''Composition action'''* Anti|-androgen is a substance that inhibits biological effects of androgenic hormones style="height:20px" * 5|bgcolor=LightCyan|[[US20060009430]] BLOTECH (2004)|bgcolor=LightCyan|Natural extracts|bgcolor=LightCyan|Palmetto berry extract (fatty acids & sterols), Pumpkin seed extract (Vitamins-B, alpha reductase + Testosterone = Dihydrotestosterone -linolenic acid, amino acids and phytosterols), Quercetin (DHTFlavonoids) and Beta-sitosterol (Rice bran, wheat germ, corn oils and soybeans)* DHT attaches to an Androgen Receptor|bgcolor=LightCyan|Fatty acids – Inhibit testosteroneSterols - Mechanism of action unknown. * DHT causes increase Quercetin results in hair loss and gradual miniaturization of the follicle, which eventually dies resulting hair losscell growth cycle.

Beta-sitosterol reduce inflammation on scalp|- style="height:20px" |bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060009427%22.PGNR.&OS=DN/20060009427&RS=DN/20060009427 US20060009427]WARNER LAMBERT(2004)|bgcolor=LightCyan|Organic compound|bgcolor=LightCyan|New class of 4-cycloalkoxy benzonitrile derivatives and salts|bgcolor=LightCyan|Acts as androgen receptor modulator and blocks formation of DHT.|- style="height:20px" |bgcolor=LightCyan|[Imagehttp:Andogen1//appft1.jpguspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050085467%22.PGNR.&OS=DN/20050085467&RS=DN/20050085467 US20050085467]WARNER LAMBERT(2004)|thumbbgcolor=LightCyan|centerOrganic compound|700pxbgcolor=LightCyan|Functions New class of Anti6-sulfonamido-quinolin-2-one and 6-sulfonamido-2-oxo-chromene derivatives.|bgcolor=LightCyan|The compounds inhibit, or decrease, activation of androgenreceptor by androgens.|- style="height:20px" |bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050118282%22.PGNR.&OS=DN/20050118282&RS=DN/20050118282 US20050118282]APHIOS Corp (2003)|bgcolor=LightCyan|Natural extracts|bgcolor=LightCyan|Supercritical fluid isolate of Saw Palmetto and Sperol (Serenoa repens berry) and their analogs or derivatives.|bgcolor=LightCyan|Modulates androgenic activity by inhibiting 5.alpha.-reductase activity.|- style="height:20px" |bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060009429%22.PGNR.&OS=DN/20060009429&RS=DN/20060009429 US20060009429]Fundacion Pablo Cassara (2003)|bgcolor=LightCyan|Nucleotide|bgcolor=LightCyan|Pharmacologically active oligonucleotides (encompass both DNA and S-DNA bond)|bgcolor=LightCyan|Oligonucleotides inhibit androgen receptor (AR) expression at very low concentrations in skin and hair follicle|- style="height:20px" |bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220030007941%22.PGNR.&OS=DN/20030007941&RS=DN/20030007941 US20030007941]PFIZER INC (2001)|bgcolor=LightCyan|Organic compound|bgcolor=LightCyan|Thyromimetic compounds (structurally similar to thyronine) with finasteride, or cyproterone acetate |bgcolor=LightCyan|Activates thyroid hormone receptors in hair follicle which in turn promote elasticisation of follicle walls and hair follicle|- style="height:20px" |bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220030073616%22.PGNR.&OS=DN/20030073616&RS=DN/20030073616 US20030073616]N/A (1995)|bgcolor=LightCyan|Peptides/nucleic acid|bgcolor=LightCyan|Bradykinin antagonist (peptide of plasma origin from kininogen precursor-kallikrein)|bgcolor=LightCyan|Inhibits synthesis of bradykinin receptors or compounds by binding to B2 receptor|- style="height:20px" |bgcolor=LightCyan|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EP0279010&F=0 EP0279010]KAO Corp (1987)|bgcolor=LightCyan|Natural extracts|bgcolor=LightCyan|Walnut extract (leaves/pericarps) with an organic solvent|bgcolor=LightCyan|Blocks formation of DHT|}

[[Image:Andogen2'''What causes hair loss?'''* A thick network of tiny veins and arteries line the outer wall of the follicle.jpg|thumb|center|700px|Table listing different functions Blood pumps through the bulb and hair via this network.* DHT accumulates in the hair follicles and roots, constricting the blood supply of Anti-androgen]]oxygen and nutrients to the hair roots; which is also seen to possibly contribute towards hair loss.

== '''How does Minoxidil ==treat hair loss?'''* A thick network of tiny veins and arteries lines Minoxidil is applied to the outer wall of scalp topically, where it dilates blood vessels in the follicle. Blood pumps through the bulb scalp and sustains the hair via this networkfollicles for longer period of time.* Minoxidil dilates blood vessels; which is also called thought to have a direct mitogenic effect on epidermal cells, as “potassium has been observed both in vitro and in vivo. Though the mechanism of its action for causing cell proliferation is not very clear, minoxidil is thought to prevent intracellular calcium entry. Calcium normally enhances epidermal growth factors to inhibit hair growth, and Minoxidil by getting converted to minoxidil sulfate acts as a potassium channel opener”agonist and enhances potassium ion permeability to prevent calcium ions from entering into cells. ([http://www.hairtransplantadvice.com/medical-hair-restoration.php Source])

[[Image:minoxidil1.jpg|thumb|center|700px|==== Functions of Monoxidil]]Vasodilators ====

[[Image:minoxidil2minoxidil1.jpg|thumb|center|700px500px|Table listing different functions Functions of Monoxidil[http://www.nurseminerva.co.uk/diagrams.htm#Diagram%201 source]]]

== Double action (Anti-androgen + Minoxidil) ==* Combination of Minoxidil + Anti-androgen (double action) composition IP Map for effective treatment of Male-Pattern Baldness Vasodilators ====

{| border="1" cellpadding="2"!width="120" bgcolor=DodgerBlue|'''Pat/Pub#'''!width="75" bgcolor=DodgerBlue|'''Nature'''!width="600" bgcolor=DodgerBlue|'''Composition'''!width="300" bgcolor=DodgerBlue|'''Composition action'''|- style="height:100px" |bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040157856%22.PGNR.&OS=DN/20040157856&RS=DN/20040157856 US20040157856]WARNER LAMBERT(2002)|bgcolor=LightCyan|Organic compound|bgcolor=LightCyan|Benzopyran compounds|bgcolor=LightCyan|Rapidly metabolizes, and causes reduced cardiovascular effects as compared to other known potassium channel openers|- style="height:100px" |bgcolor=LightCyan|[Imagehttp:Doubleaction1//appft1.jpguspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050053572%22.PGNR.&OS=DN/20050053572&RS=DN/20050053572 US20050053572]LG HOUSEHOLD & HEALTH CARE(2001)|thumbbgcolor=LightCyan|centerNatural extracts|700pxbgcolor=LightCyan|Functions of Sophora flavescens extract (Antialkaloids & flavonoids, luteolin-androgen + Minoxidil7-glucose and cytosine)]]Hinokitiol (Taiwan hinoki oil, Aomori, Western Red Cedar oil) and Nicotinamide (Vitamin B complex)|bgcolor=LightCyan|Promotes function of cell activity and dilates blood vessels|}

[[Image:Doubleaction2.jpg|thumb|center|700px|Table listing different functions of === Double action (Anti-androgen + MinoxidilVasodilator)]]===* Combination of Vasodilator + Anti-androgen (double action) composition for effective treatment of Male-Pattern Baldness.

== Hair matrix cell activator =='''What is the problem with using only Anti-androgen therapy?'''* Stem cells of the hair follicle are gathered Anti-androgen is not effective in addressing the basal layer issue of the outer root sheath bulgevasocontriction around hair follicles due to sebum oil build up.* It is from these cells that matrix cells are formedAnti-androgen only prevents binding of DHT to androgen receptors.* Growth and differentiation of the matrix cells are under However, the influence of substances produced by cells effects of improper oxygen and nutrient supply to the dermal papillabrain due to vasocontriction still remains and gradually causes hair loss. [[Image:Hair matrix.jpg|thumb|center|700px|Functions of Hair matrix cell activator ]]

[[Image:Hair matrix1.jpg|thumb|center|700px|Table listing different functions '''What is the problem with using only Vasodilator (or Minoxidil only) therapy?'''* Vasodilator or Minoxidil-based products are generally not effective in stopping hair loss as vasodilators (or Minoxidil) do not block the harmful effects of Hair matrix cell activator ]]DHT in the scalp and hair follicles. * Vasodilators or Minoxidil simply dilate blood vessels in the scalp. However, the harmful DHT still gets produced in the body, enters the scalp and hair follicles causing hair loss.

== Sebum Production Inhibitor =='''How is the combination of Anti-androgens and Vasodilator (or Minoxidil) effective?'''* Sebum, a complex mixture Anti-androgens target the problem of lipid substances, is secreted from sebaceous glands associated with hair folliclesDHT binding to androgen receptors and prevents follicle miniaturization.* The inhibitor blocks the excessive sebum production produces greasy effect on hair Vasodilators like Minoxidil cause vasodilation and scalp and also responsible for thinning and loosing therefore improve supply of oxygen and nutrients to the hairfollicle and roots.* Combination therapy therefore proves to be much more effective than individual therapy.

==== Functions of (Anti-androgen + Vasodilators) ==== [http://www.revivogen.com/revivogen/work.html Anti-androgen ]and [http://www.xandrox.net/articles/article01.htm Minoxidil][[Image:Sebum1Doubleaction1.jpg|thumb|center|700px500px|Functions of Sebum Production Inhibitor(Anti-androgen + Vasodilators)]]

==== IP Map for (Anti-androgen + Vasodilators) ===={| border="1" cellpadding="3"!width="120" bgcolor=DodgerBlue|'''Pat/Pub#'''!width="75" bgcolor=DodgerBlue|'''Nature'''!width="500" bgcolor=DodgerBlue|'''Composition''' !width="500" bgcolor=DodgerBlue|'''Composition action'''|- style="height:100px" |bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060052405%22.PGNR.&OS=DN/20060052405&RS=DN/20060052405 US20060052405] N/A(2000)|bgcolor=LightCyan|Peptides|bgcolor=LightCyan|Testosterone blocker or vascular toner (Flutamide, cyproterone acetate, spironolactone, progesterone, or analogs or derivatives) and minoxidil mixed along with non-retinoid penetration enhancer and sunscreen|bgcolor=LightCyan|Inhibits 5.alpha.-reductase activity (block DHT) and increase blood flow on the scalp|- style="height:100px" |bgcolor=LightCyan|[Imagehttp:Sebum2//appft1.jpguspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050123577%22.PGNR.&OS=DN/20050123577&RS=DN/20050123577 US20050123577] L'OREAL(2000)|thumbbgcolor=LightCyan|centerPeptides|700pxbgcolor=LightCyan|Table listing different functions Prostaglandin (polyunsaturated fatty acids) EP-2, EP-3 EP-4 receptor agonist with Minoxidil, 2,4-diaminopyrimidine 3-oxide, and Aminexil, cyclic AMP|bgcolor=LightCyan|Minoxidil (designed to mimic nitric oxide's effects) grows hair via prostaglandin-H synthase stimulation. EP-3 and EP-4 are expressed in anagen hair follicles which induce a reduction in the level of Sebum Production Inhibitor]cAMP|- style="height:100px" |bgcolor=LightCyan|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6447762.PN.&OS=PN/6447762&RS=PN/6447762 US6447762]COLOMER GROUP(1999)|bgcolor=LightCyan|Natural extract|bgcolor=LightCyan|Hop extract (oil contains terpenes and humulene), Rosemary extract (hydroalcohol), Swertia extract (glycol with a swertiamarin), Silanodiol salicylate (biologically active silicon compound)|bgcolor=LightCyan|Inhibits activity of 5-alpha-reductase, protects follicular cell membranes by neutralizing action of oxidation reaction in tissues, stimulates hair follicles and blood circulation to the hair root, supplies oxygen and nutrients to base of follicle, retains humidity, avoids dehydration of scalp|}

== Composition nature = Hair matrix cell activator ===Hair matrix cell activator is a substance that acts at the matrix cells in the hair follicle preventing their degradation.

[[Image:Composition'''What causes hair loss?'''* Stem cells are interspersed within the basal layer of the outer root sheath and in an area called the bulge.jpg|thumb|center|700px|Table listing different functions * Stem cells migrate to hair matrix where they start to divide and differentiate, under the influence of Composition nature substances produced by cells of the dermal papilla.* Perifollicular matrix]]cells undergo slow degradation which prevents follicle stimulation.* Hair follicle activation is required for hair growth and thus inhibition of follicle activation eventually leads to hair loss.

=== Focus on patents =Functions of Hair matrix cell activator ====[http://www.ijdb.ehu.es/fullaccess/fulltext.04023/ft163.pdf Hair matrix cell activator][[Image:FocusHair matrix.jpg|thumb|center|700px500px|Focus Functions of patentsHair matrix cell activator ]]

=== Focus Technology mapping based on Technologypatents analyzed ===[[Image:Technologyfocus.jpg|thumb|center|700px|Technology focus]]

{| border="1" cellpadding= Distribution "11", style="#008080"!width="120" bgcolor=DodgerBlue|'''Year'''!width="200" bgcolor=DodgerBlue|'''Organic Compound'''!width="200" bgcolor=DodgerBlue|'''Natural extracts''' !width="200" bgcolor=DodgerBlue|'''Peptides'''!width="200" bgcolor=DodgerBlue|'''Nucleotides'''!width="200" bgcolor=DodgerBlue|'''Natural extract + Organic comp'''|- style="height:10px"|bgcolor=LightCyan|2005 |bgcolor=LightCyan|....|bgcolor=LightCyan|.... |bgcolor=LightCyan|....|bgcolor=LightCyan|....|bgcolor=LightCyan|UNILEVER (1)|- |bgcolor=LightCyan|2004 |bgcolor=LightCyan|WARNER (1)|bgcolor=LightCyan|BLOTECH (1) |bgcolor=LightCyan|....|bgcolor=LightCyan|....|bgcolor=LightCyan|KAO (1)|- |bgcolor=LightCyan|2003|bgcolor=LightCyan|WARNER (1)|bgcolor=LightCyan|APHIOS (1) |bgcolor=LightCyan|....|bgcolor=LightCyan|FUNDACION (1)|bgcolor=LightCyan|....|- |bgcolor=LightCyan|2002|bgcolor=LightCyan|WARNER (1)|bgcolor=LightCyan|.... |bgcolor=LightCyan|....|bgcolor=LightCyan|....|bgcolor=LightCyan|....|- |bgcolor=LightCyan|2001|bgcolor=LightCyan |PFIZER (1)|bgcolor=LightCyan|LG HEALTH-CARE (1) |bgcolor=LightCyan|....|bgcolor=LightCyan|....|bgcolor=LightCyan|....|- |bgcolor=LightCyan|2000|bgcolor=LightCyan|....|bgcolor=LightCyan|.... |bgcolor=LightCyan|L’OREAL (1) / N/A (1)|bgcolor=LightCyan|....|bgcolor=LightCyan|....|- |bgcolor=LightCyan|1999|bgcolor=LightCyan|SHISEDIO (1)|bgcolor=LightCyan|COLOMER (1) |bgcolor=LightCyan|....|bgcolor=LightCyan|....|bgcolor=LightCyan|....|- |bgcolor=LightCyan|1998|bgcolor=LightCyan|....|bgcolor=LightCyan|.... |bgcolor=LightCyan|L’OREAL (1)|bgcolor=LightCyan|....|bgcolor=LightCyan|....|-|bgcolor=LightCyan|1995|bgcolor=LightCyan|....|bgcolor=LightCyan|.... |bgcolor=LightCyan|N/A (1)|bgcolor=LightCyan|....|bgcolor=LightCyan|.... |-|bgcolor=LightCyan|1987|bgcolor=LightCyan|....|bgcolor=LightCyan|KAO (1)|bgcolor=LightCyan|....|bgcolor=LightCyan|....|bgcolor=LightCyan|....|-|bgcolor=LightCyan|1982|bgcolor=LightCyan|UNILEVER (1)|bgcolor=LightCyan|....|bgcolor=LightCyan|....|bgcolor=LightCyan|....|bgcolor=LightCyan|....|}=== Focus of patents === {| border="1" cellpadding="17", style="#008080"!width="800" bgcolor=DodgerBlue|'''Focus of patents'''!width="150" bgcolor=DodgerBlue|'''Patent no.'''!width="100" bgcolor=DodgerBlue|'''Rec. no.'''|- |bgcolor=LightCyan|2-substituted oxyphenyl alkanamide derivative having excellent hair growth effect.|bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220020052498%22.PGNR.&OS=DN/20020052498&RS=DN/20020052498 US20020052498]|bgcolor=LightCyan|1|- |bgcolor=LightCyan|Thyromimetic compounds, and its role in treating hair loss|bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220030007941%22.PGNR.&OS=DN/20030007941&RS=DN/20030007941 US20030007941]|bgcolor=LightCyan|2|- |bgcolor=LightCyan|Saw Palmetto berry extract, pumpkin seed extract, sitosterol and quercetin for the treatment and prevention of the biologically detrimental effects of DHT|bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060009430%22.PGNR.&OS=DN/20060009430&RS=DN/20060009430 US20060009430]|bgcolor=LightCyan|3|- |bgcolor=LightCyan|4-cycloalkoxy benzonitriles and its use as androgen receptor modulators|bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060009427%22.PGNR.&OS=DN/20060009427&RS=DN/20060009427 US20060009427]|bgcolor=LightCyan|4|- |bgcolor=LightCyan|Supercritical fluid isolate of Saw Palmetto, Sperol for inhibition of 5-.alpha.-reductase activity|bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050118282%22.PGNR.&OS=DN/20050118282&RS=DN/20050118282 US20050118282]|bgcolor=LightCyan|5|- |bgcolor=LightCyan|New class of quinolin-2-ones and chromen-2-ones andtheir use as androgen receptor antagonists|bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050085467%22.PGNR.&OS=DN/20050085467&RS=DN/20050085467 US20050085467]|bgcolor=LightCyan|6|- |bgcolor=LightCyan|Antiandrogen oligonucleotides usable for the treatment of dermatological androgen-related disorders|bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060009429%22.PGNR.&OS=DN/20060009429&RS=DN/20060009429 US20060009429]|bgcolor=LightCyan|7|- |bgcolor=LightCyan|Bradykinin antagonists for stimulating or inducing hair growth and/or arresting hair loss|bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220030073616%22.PGNR.&OS=DN/20030073616&RS=DN/20030073616 US20030073616]|bgcolor=LightCyan|8|- |bgcolor=LightCyan|Extract from walnut leaves and/or pericarps as 5 alpha -reductase inhibitor|bgcolor=LightCyan|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EP0279010&F=0 EP0279010]|bgcolor=LightCyan|9|- |bgcolor=LightCyan|Stimulating hair growth using benzopyrans|bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040157856%22.PGNR.&OS=DN/20040157856&RS=DN/20040157856 US20040157856]|bgcolor=LightCyan|10|- |bgcolor=LightCyan|Sophora flavescens extract, Coicis semen extract, clove extract, etc for promoting hair growth, function of cell activity and dilating peripheral blood vessels.|bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050053572%22.PGNR.&OS=DN/20050053572&RS=DN/20050053572 US20050053572]|bgcolor=LightCyan|11|- |bgcolor=LightCyan|Compositions to prevent or reduce hair loss|bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060052405%22.PGNR.&OS=DN/20060052405&RS=DN/20060052405 US20060052405]|bgcolor=LightCyan|12|- |bgcolor=LightCyan|Prostaglandin EP-3 receptor antagonists for reducing hair loss|bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050123577%22.PGNR.&OS=DN/20050123577&RS=DN/20050123577 US20050123577]|bgcolor=LightCyan|13|- |bgcolor=LightCyan|Synergic effect arising from the interaction of active ingredients, consisting of three plant extracts and a synthetic organosilicic compound for prevent hair loss and stimulate hair growth|bgcolor=LightCyan|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6447762.PN.&OS=PN/6447762&RS=PN/6447762 US6447762]|bgcolor=LightCyan|14|- |bgcolor=LightCyan|Metalloprotease inhibitors to induce and/or stimulate the growth|bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040071647%22.PGNR.&OS=DN/20040071647&RS=DN/20040071647 US20040071647]|bgcolor=LightCyan|15|- |bgcolor=LightCyan|Method of decreasing sebum production and pore size|bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050277699%22.PGNR.&OS=DN/20050277699&RS=DN/20050277699 US20050277699 ]|bgcolor=LightCyan|16|- |bgcolor=LightCyan|Method for reducing sebum on different aspects the hair and skin|bgcolor=LightCyan|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4529587.PN.&OS=PN/4529587&RS=PN/4529587 US4529587]|bgcolor=LightCyan|17|} === Technology focus===[[Image:Technologyfocus2.jpg|thumb|center|700px|Technology focus]]=== Distribution of patents ===

=== Distribution based on = By patent types ====

=== Distribution of = By key ingredients ====[[Image:keykey1.jpg|thumb|center|700px|Distribution of key ingredients]]

'''Other attributes of the key ingredients'''[[Image:Otherattributes.jpg|thumb|center|1000px|Other attributes of the key ingredients]]  === Distribution based on = By target diseases disease ====

==== Key ingredients vs. Target disease/disorder ====[[Image:key&targettarget1.jpg|thumb|center|1000px|Key ingredients vs. Target disease]]

==== Target species ====

 ==== Mode of administration ====

==== Product type vs. Product form ====

=== Distribution of patents based on target diseases Pathways associated with hair matrix cell activation===[[Image:Distriution.jpg|thumb|center|700px|Distribution of patents based on target diseases]]

=== Distribution * '''Wnt pathway:''' Maintains hair-inducing activity of patents based on application ===the dermal papilla.[[Image* '''Hedgehog pathway:application''' Sonic hedgehog (SHH) signaling plays a critical role in hair follicle development.jpg|thumb|center|700px|Distribution Sonic hedgehog gene. Sonic hedgehog, SHH for short, helps guide hair follicles from a resting stage into growth activity. SHH is particularly important in the embryonic formation of patents based hair follicles.* '''STAT pathway'''* '''TGF beta/BMP Pathway:''' Bone morphogenetic protein (BMP) signaling have been implicated in the regulation of both proliferation and differentiation in the hair follicle. BMP2 is expressed in the embryonic ectoderm, but then localizes to the early hair follicle placode and underlying mesenchyme. BMP4 is expressed in the early dermal condensate. Research results show that BMPs are a key component of the signaling network controlling hair development and are required to induce the genetic program regulating hair shaft differentiation in the anagen hair follicle. Transforming growth factor beta (TGF-beta), inhibits mitogen - induced dermal papilla cell proliferation* '''FGF Pathway:''' Fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF) potentiate the growth of dermal papilla cells. It is proposed that these proteins increase the synthesis of stromelysin (an enzyme, matrix metalloproteinase) which acts on application]]the papilla cells and accelerates their growth.* '''MAPK Pathway:''' Mitogen-activated protein kinase (MAPK) activation, increases keratinocyte turnover.* '''NOTCH Pathway''': Notch-1 is expressed in ectodermal-derived cells of the follicle, in the inner cells of the embryonic placode and the follicle bulb, and in the suprabasal cells of the mature outer root sheath. Delta-1, one of the three ligands is only expressed during embryonic follicle development and is exclusive to the mesenchymal cells of the pre-papilla located beneath the follicle placode, and appears to promote and accelerate placode formation, while suppressing placode formation in surrounding cells. Other ligands, Serrate 1 and Serrate 2, are expressed in matrix cells destined to form the inner root sheath and hair shaft.

== Questions Dolcera Answers ==Players of WNT inhibition Pathway ==== [[Image:wnt.jpg|thumb|right|200 px|Wnt inhibition]]{| border="1" cellpadding="15", style="#008080"!width="150" bgcolor=DodgerBlue|'''Patent no.'''!width="200" bgcolor=DodgerBlue|'''Key compound'''!width="200" bgcolor=DodgerBlue|'''Players of inhibition'''|- style="height:10px"|bgcolor=lightyellow|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6664247.PN.&OS=PN/6664247&RS=PN/6664247 US6664247]|bgcolor=lightyellow|Pyrazole compounds |bgcolor=lightyellow|GSK3|-|bgcolor=lightyellow|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6989385.PN.&OS=PN/6989385&RS=PN/6989385 US6989385]|bgcolor=lightyellow|Pyrazole compounds |bgcolor=lightyellow|GSK3|-|bgcolor=lightyellow|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005012256&F=0 WO2005012256]|bgcolor=lightyellow|Pyrazole compounds |bgcolor=lightyellow|CDK,GSK3|-|bgcolor=LightCyan|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6974819.PN.&OS=PN/6974819&RS=PN/6974819 US6974819]|bgcolor=LightCyan|Pyrimidine derivative|bgcolor=LightCyan|GSK3|-|bgcolor=LightCyan|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6743791.PN.&OS=PN/6743791&RS=PN/6743791 US6743791]|bgcolor=LightCyan|Heterocyclic compounds|bgcolor=LightCyan|AKT3, GSK-3, ERK2|-|bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050277773%22.PGNR.&OS=DN/20050277773&RS=DN/20050277773 US20050277773]|bgcolor=LightCyan|Pyrrolo[3,2-d]pyrimidine derivatives |bgcolor=LightCyan|GSK3|-|bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040072836%22.PGNR.&OS=DN/20040072836&RS=DN/20040072836 US20040072836]|bgcolor=LightCyan|Aza-oxindole derivatives |bgcolor=LightCyan|GSK3, AKT, PKC|-|bgcolor=LightCyan|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EP1477489&F=0 EP1477489]|bgcolor=LightCyan|Pyrrolopyrimidine derivatives |bgcolor=LightCyan|GSK3|-|bgcolor=LightCyan|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO0056710&F=0 WO0056710]|bgcolor=LightCyan|3-(Anilinomethylene) oxindoles |bgcolor=LightCyan|GSK3, AKT, PKC|-|bgcolor=LightCyan|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO03011287&F=0 WO2003011287]|bgcolor=LightCyan|Pyrazolon derivatives |bgcolor=LightCyan|GSK3, ß-catenin|-|bgcolor=LightCyan|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6924141.PN.&OS=PN/6924141&RS=PN/6924141 US6924141]|bgcolor=LightCyan|Lithium chloride, Wnt3/4/ 7 |bgcolor=LightCyan|ß-catenin, GSK3, Wnt|-|bgcolor=LightCyan|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6706685.PN.&OS=PN/6706685&RS=PN/6706685 US6706685]|bgcolor=LightCyan|Peptide sequence |bgcolor=LightCyan|ß-catenin|-|bgcolor=LightCyan|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6683048.PN.&OS=PN/6683048&RS=PN/6683048 US6683048]|bgcolor=LightCyan|Peptide sequence |bgcolor=LightCyan|a-catenin, ß-catenin|-|bgcolor=LightCyan|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6677116.PN.&OS=PN/6677116&RS=PN/6677116 US6677116]|bgcolor=LightCyan|Peptide sequence LXXLL|bgcolor=LightCyan|ß-catenin|-|bgcolor=LightCyan|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6303576.PN.&OS=PN/6303576&RS=PN/6303576 US6303576]|bgcolor=LightCyan|Peptide sequence LXXLL|bgcolor=LightCyan|ß-catenin|}

==== Role of Pyrazole compounds in Wnt Pathway===='''What’s hot?Pyrazole'''* What compositions/ approaches are '''Pyrazole''' (C3H4N2) refers both to the most promising?class of simple aromatic ring organic compounds of the heterocyclic series characterized by a 5-membered ring structure composed of three carbon atoms and two nitrogen atoms in adjacent positions and to the unsubstituted parent compound. Being so composed and having pharmacological effects on humans, they are classified as alkaloids although they are not known to occur in nature.* What can I license?Pyrazoles are produced synthetically through the reaction of a,ß-unsaturated aldehydes with hydrazine and subsequent dehydrogenation [[Image:pyrazole1.jpg|thumb|center|500px|Pyrazole (C3H4N2)]]* Can you map blockbuster products to Pyrazoles are used for their patents?analgesic, anti-inflammatory, antipyretic, antiarrhythmic, tranquilizing, muscle relaxing, psychoanaleptic, anticonvulsant, monoamineoxidase inhibiting, antidiabetic and antibacterial activities.* Structurally related compounds are pyrazoline and pyrazolidine.[[Image:pyrazole2.jpg|thumb|center|500px|Structurally related compounds]]

'''Can you save me some time?'''==== GSK3 inhibition by pyrazole compounds ====* What combinations[[Image:bold3.jpg]]{| border="1" cellpadding="2", style="#008080"!width="350"|[http:/ compounds have already been tried/patft1.uspto.gov/netacgi/nph-Parser?TERM1=6989385+&Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=0&f=S&l=50 US6989385]* Is any empirical data available[[Image:US6989385.jpg]]!width="350"|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6664247.PN.&OS=PN/6664247&RS=PN/6664247 US6664247] * Can you tell me the side effects[[Image:US6664247.jpg]]!width="350"|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005012256&F=0 WO2005012256] [[Image:WO2005012256.jpg]]|- |bgcolor=lightcyan|R1=T-Ring D, wherein T is a valence bond and Ring D = 5-6 membered aryl or heteroaryl ring;

R2 = hydrogen or C1-4 aliphatic and R2'''Where should I focus my R&D investment?'''* What are the most promising approaches?* Where’s the ‘white space’ for me to play in?= hydrogen;

'''What should I do |bgcolor=lightcyan|X = R1-A-NR4- or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, S02, C=O, NRg(C=O) or O(C=O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in this geography?'''* What are my competitors up to in this geography?* What are my strengths/ weaknesses here?length;

'''What’s my competition up R1 is hydrogen; carbocyclic or heterocyclic group having from 3 to?'''12 ring members; or C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C1-4 hydrocarbyloxy, amino, mono- or di-C1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from 0, S, NH, SO, S02;

* What’s my top competitor investing in?* Are there any loopholes in their patents?* When are their patents expiring?* Will R2 is hydrogen; halogen; C1-4 alkoxy (e.g. methoxy); or a competitor emerge C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy); R3 is selected from nowhere hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and surprise me?* What are the crowded areas?

R4 is hydrogen or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy). |bgcolor=lightcyan|X is a groupR1-A-NR4-or a 5-or 6-membered carbocyclic or heterocyclic ring;A is a bond,SO2, C=O, NRg (C=O) or O(C=O) wherein Rg is hydrogen orC14 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy;Y is a bond or an alkylene chain of 1,2 or 3 carbon atoms in length;R'''How do I play defense?'''is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e. g. fluorine), hydroxy, C1-4 hydrocarbyloxy, amino, mono-ordi-Cl 4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected fromO, S, NH, SO, SO2 ;R2 is hydrogen; halogen;C14 alkoxy (e. g. methoxy); or aC14 hydrocarbyl group optionally substituted by halogen (e. g. fluorine), hydroxyl orC14 alkoxy (e. g. methoxy);R3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; andR4 is hydrogen or a C1-4 hydrocarbyl group optionally substituted by halogen (e. g. fluorine), hydroxyl or C1-4 alkoxy (e. g. methoxy).* What should my blocking/reactive strategies be?|}

Yes, new Combinations can be made with '''natural productsBasic Structure''' based on IP study* Walnut extract containing [[Image:5ar.jpg]] inhibitor (as anti-androgen) and Flavnones (for vasodilation).* Sophora Flavnones (for vasodilation) in combination with Saw Palmetto berry (as anti-androgen).

'''Note[[Image:''' The above combinations are based on limited study and are only possible examplespyrazol1.jpeg]]

=== Technology trends ==='''Patent Number''': US7008948 * Use of saw palmetto berry for treating alopecia was first patented in 1996.* Since then, 144 patents (including family patents) have been filed till 2006.* Most patents use saw palmetto berry in combination with other products.'''Applicant''': Vertex Pharmaceuticals Incorporated[[Image'''Title''':Technology1.jpg|thumb|center|700px|Technology trends]]Fused pyrimidyl pyrazole compounds useful as protein kinase inhibitors

'''Basic Structure''' [[Image:pyrazol2.jpeg]] [[Derivatives of pyrimidine-pyrazole amine disclosed in US7008948 patent]] '''Patent Number''': US6977262'''Assignee''': Mitsubishi Pharma Corporation'''Title''': Dihydropyrazolopyridine compounds and pharmaceutical use thereof '''Basic Structure''': [[Image:pyrazol3.jpeg]] [[Derivatives of pyrimidine-pyrazole amine disclosed in US6977262 patent]] ----'''Patent Number''': US6664247'''Assignee''': Vertex Pharmaceuticals Incorporated'''Title''': Pyrazole compounds useful as protein kinase inhibitors''' '''Basic Structure''':  [[Image:pyrazol4.jpeg]] [[Derivatives of pyrimidine-pyrazole amine disclosed in US6664247 patent]] ----'''Patent Number''': US2004224944'''Assignee''': VERTEX PHARMACEUTICALS INC'''Title''': Pyrazole compounds useful as protein kinase inhibitors '''Basic Structure''':  [[Image:pyrazol5.jpeg]] [[Derivatives of pyrimidine-pyrazole amine disclosed in US2004224944 patent]] [[Other derivates for alopecia]] === New opportunities = GSK-3 Inhibition Mechanism - Phosphorylation====Yes* ''GSK-3 inhibition targets treatment of chemotherapy-induced alopecia'' [http://www.biomedcentral.com/1471-2199/5/15 source]* In the canonical Wnt signaling cascade, adenomatous polyposis coli (APC), axin, and GSK3 constitute the IP studies provide new opportunities so-called destruction complex, which controls the stability of beta-catenin. It is generally believed that four conserved Ser/Thr residues in the following areaN terminus of beta-catenin are the pivotal targets for the constitutively active serine kinase GSK3. GSK3 covalently modifies beta-catenin by attaching phosphate groups (from ATP) to serine, and threonine residues. In so doing, the functional properties of the protein kinase’s substrate (beta-catenin) are modified. * Sophora Flavescens contain flavnoidsIn the absence of Wnt signals, glycogen synthase kinase (GSK) is presumed to phosphorylate the N-terminal end of beta-catenin, thus promote degradation of beta-catenin and subsequent ubiquitination and proteasomal targeting. * Natural extract Sophora Flavescens cited Exposure of cells to Wnts leads to inactivation of GSK-3 through an as yet unclear mechanism.The phosphoprotein Dishevelled is required, after receptor-ligand interaction, to transduce the signal that results in LG patent the inactivation of 2001GSK-3.As a result, beta-catenin is dephosphorylated and escapes the ubiqduitylation-dependent destruction machinery. * Research shows fewer than 7 patents based Unphosphorylated beta-catanin accumulates in the cytoplasm and translocates to the nucleus, where it can associate with the TCF/LEFs and become a transcriptional transactivator. '''[[More details on Sophora Flavescens GSK-3]]''' '''Key points''' * Beta-catenin phosphorylation at serine 45 (Ser45), threonine 41 (Thr41), Ser37, and Ser33 is critical for beta-catenin degradation. [http://jb.oxfordjournals.org/cgi/content/abstract/132/5/697 source]* Regulation of beta-catenin phosphorylation is a central part of the canonical Wnt signaling pathway. [http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowPDF&ProduktNr=223838&ArtikelNr=66755&filename=66755.pdf source]* Ser-X-X-X-Ser (X is any amino acid) motif is obligatory for beta-catenin phosphorylation by GSK3.[http://lib.bioinfo.pl/auth:He,X source]* Beta-catenin phosphorylation/degradation and its regulation by Wnt can occur normally in the absence of Thr41 as long as the Ser-X-X-X-Ser motif/spacing is preserved. [httSp://pubs.acs.org/cgi-bin/abstract.cgi/bichaw/2006/45/i16/abs/bi0601149.html source] '''GK3 Inhibition:'''  * GSK3 is regulated by phosphorylation.* Phosphorylation of GSK3beta on Ser9 (Ser21 in GSK3alpha) by protein kinase B (PKB) causes its inactivation is the primary mechanism responsible for growth factor inhibition of this kinase. Activation of GSK3beta is dependent upon the phosphorylation of Tyr216 (Tyr279 in GSK3alpha). Upon activation, it has been shown to phosphorylate a number of different cellular proteins, including p53, c-Myc, c-Jun, heat shock factor-1 (HSF-1), beta-catenin and cyclin D1. [http://www.bioreagents.com/index.cfm/fuseaction/products.detail/CatNbr/OPA1-03082 source]* GSK3 is inhibited by phosphorylation of serine-9 or serine-21 in GSK3beta and GSK3alpha, respectively. [http://lib.bioinfo.pl/auth:Friedman,AB source]* GSK3’s substrate specificity is unique in that phosphorylation of substrate only occurs if a phosphoserine or phosphotyrosine is present four residues C-terminal to the site of GSK phosphorylation. [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11430833&dopt=Abstract source]* A phosphorylation cascade starts from GSK3 itself and initiates it in beta-catenin. [http://www.genesdev.org/cgi/content/full/16/16/2073 source]* Thus our goal is to stop the phosphorylation of the serine and threonine residue of GSK3.* The figure below illustrates the phosphorylation mechanism of serine and threonine by ATP.  [[image:GSK3_phosphorylation.jpg|400 px|center|thumb|Phosphorylation mechanism [http://images.google.com/images?q=tbn:DGnhgZ7y7pSejM:bass.bio.uci.edu/~hudel/bs99a/lecture26/phosphoaa.gif source]]]  * We can't stop conversion of ADP to ATP that relaseas Phosphorous group causing Phosphorylation. * We can only block the oxygen atom on serine and threonine as a result which will in turn stop Phosphorylation. * The two probable ways of blocking the oxygen atom are (a) As oxygen is a Lewis acid with strong electron donating capacity, so usually a strong electron pair acceptor can easily bind to oxygen atom and preventing phosphorylation or (b) breaking of the -OH bond with the carbon atom.  '''Serine - pyrazole reaction''' [[image:serine-pyrazol.jpg|600 px|center|thumb|Serine and Pyrazole reaction [http://www.genome.ad.jp/dbget-bin/www_bget?rn+R03134 source]]] * The T-loop of GSK-3 is tyrosine phosphorylated at Y216 and Y279 in GSK-3b and GSK-3a, respectively, but not threonine phosphorylated. Y216/Y279 phosphorylation could play a role in forcing open the substrate (e.g, beta-catanin)-binding site. * Thus, T-loop tyrosine might facilitate substrate phosphorylation but is not strictly required for kinase activity. * Stimulation of cells with pyrazole compounds cause inactivation of GSK-3 through phosphorylation (S9 of GSK-3 beta and S21 of GSK-3 alpha), which inhibits GSK-3 activity. Thus leading to dephosphorylation of substrates (e.g., beta-catanin) resulting in their functional activation and consequent increased hair loss follicle morphogenisis. * Phosphorylation of S9/S21 creates a primed pesudosubstrate that binds intramolecularly to the positively charged pocket of the GSK-3. This folding precludes phosphorylation of substrates (eg., beta-catanin) because the catalytic groove is occupied. The mechanism of inhibition is competitive.  * A consequence of this is that primed substrates, in high enough concentrations, out-compete the pesudosubstrate and thus become phosphorylated. * Thus, small molecule inhibitors modeled to fit in the positively charged pocket of the GSK-3 kinease domain could potentially be very effective for selective inhibition of primed substrates. '''Proposed mechanisms to regulate GSK-3''' [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12615961 source] # inactivation of GSK-3 through serine phosphorylation# activation of GSK-3 through tyrosine phosphorylation# inactivation of GSK-3 through tyrosine dephosphorylation# Covalant modifications of substrates through priming phosphorylation# inhibition or facilation of GSK-3 mediated substrate phosphorylation thriugh interation of GSK-3 with binding or scaffolding proteins# targeting of GSK-3 to different subcellular localizations# differential usage of isoforms or splice variants to alter subcellular localization or substrate specificity# integration of parellel signals conveyed by a signal stimulus. '''Key Finding'''* '''Pyrazole compounds with inhibition constant (Ki) of <0.1 mM''' are a good starting point for developing molecules that can inhibit serine/threonine protein kinase (such as GSK-3) and the proteins they help to regulate. [http://www.chemistry.org/portal/a/c/s/1/acsdisplay.html?DOC=patentwatch%5Carchive%5C011204_patentwatch.html source] === Pathway associated with anti-androgen === * Dihydrotestosterone ** Formed by peripheral conversion of testosterone by 5-alpha reductase** Binds to androgen receptor on susceptible hair follicles* Hormone-receptor complex activates genes responsible for gradual transformation of large terminal follicles to miniaturized (progressive diminution of hair shaft diameter and length in response to systemic androgens) follicles [[Image:5-alpha-reductase inhibition.jpeg|center|500 px]] ==== Structure-Activity Relationships(SARs) ====[[Image:SAR_map.gif|center|720px]] === Pathway associated with Minoxidil (vasodilators) ===Minoxidil is a well know drug used for the treatment of alopecia.A co-relation between Sesquiterpene lactone (Helenalin) produced from Arnica montana and Minoxidil is illustrated in the figure below. Arnica montana, a Vasodilator, acts on the NO/cGMP Pathway through T-cells, B-cells and epithelial cells & abrogates kappa B-driven gene expression.[[image:vasodiator-rev.jpg|800 px|center]] == Alopecia IPMap == [http://www.dolcera.com/client/d8r3/hairloss_map.htm Dolcera IPMap for Alopecia]     == Patent activity in China =====Treatment approaches==={|border="2" cellspacing="0" cellpadding="4" width="100%"|align = "center"|'''Treatment approach'''|align = "center"|'''Patent number'''|align = "center"|'''Priority year'''|align = "center"|'''Assignee/Inventor'''|-|rowspan = "7"|Vasodilators|[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN200510107497.8&leixin=fmzl&title=治疗瘀血阻滞型脱发的中草药汤剂及制备方法&ipc=A61K36/804(2006.01)I CN1772105]|2005|叶明伟|-|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=CN1772139&F=0 CN1772139]|2005|王亚杰|-|[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN03139861.8&leixin=fmzl&title=一种可用于治疗脱发、白发的天然中草药提取组合物及应用&ipc=A61K35/78 CN1569080]|2003|谈汝标|-|[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN02155404.8&leixin=fmzl&title=毛囊激活液&ipc=A61K35/78 CN1506103]|2002|赵章光|-|[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN01127395.X&leixin=fmzl&title=一种止脱生发药物及其制备方法&ipc=A61K35/78 CN1403100]|2001|范希田|-|[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN96116925.7&leixin=fmzl&title=免洗养发生发香波&ipc=C11D3/48 CN1165181]|1996|殷国健|-|[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN88103853.9&leixin=fmzl&title=一种通络生发香波&ipc=A61K7/06 CN1031022]|1988|天津市轻工业化学研究所|-|Hair matrix activator|[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN02111941.4&leixin=fmzl&title=一种含中西药复方的育发剂&ipc=A61K7/06 CN1463693]|2002|朱静建|-|Anti-androgen <nowiki>+</nowiki> Vasodilator|[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN96109964.X&leixin=fmzl&title=一种治疗脂溢性脱发的高效低副作用外用药物&ipc=A61K35/78 CN1150043]|1996|梅晓春|-|} === Details of treatment approaches=== {|border="2" cellspacing="0" cellpadding="4" width="100%" align="left"|align = "center"|'''Patent number'''|align = "center"|'''Patent title'''|align = "center"|'''Treatment approach'''|align = "center"|'''Composition nature'''|align = "center"|'''Composition'''|align = "center"|'''Composition action'''|-|align = "justify"|[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN200510107497.8&leixin=fmzl&title=治疗瘀血阻滞型脱发的中草药汤剂及制备方法&ipc=A61K36/804(2006.01)I CN1772105]<br>YE MINGWEI (CN)<br>叶明伟 (2005)|align = "justify"|Chinese herbal medicine decoction for treating blood stasis obstruction type alopecia and its prepn<br>治疗瘀血阻滞型脱发的中草药汤剂及制备方法|align = "justify"|Vasodilators|align = "justify"|Herbal extract|align = "justify"|Astragalus root, prepared rhizome of rehmannia, white peony root, angelica, peach kernel and sufflower|align = "justify"|Promote blood circulation|-|align = "justify"|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=CN1772139&F=0 CN1772139<br>]WANG YAJIE (CN)<br>王亚杰 2005|align = "justify"|Alopecia areata treating medicine<br>一种治疗斑秃的药物|align = "justify"|Vasodilators|align = "justify"|Herbal extract|align = "justify"|Pinellia tuber, fleeceflower root, arborvitae seed, chickení s gizzard membrane, prepared rhizome of rehmannia, Poris cocos, Codonopsis pilosula, etc|align = "justify"|Promote blood circulation|-|align = "justify"|[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN03139861.8&leixin=fmzl&title=一种可用于治疗脱发、白发的天然中草药提取组合物及应用&ipc=A61K35/78 CN1569080]<br>TAN RUBIAO (CN)<br>谈汝标 2003|align = "justify"|Natural Chinese herb composition for treating alopecia and leucotrichia and its application<br>一种可用于治疗脱发、白发的天然中草药提取组合物及应用|align = "justify"|Vasodilators|align = "justify"|Herbal extract|align = "justify"|Ginger, Cinnamomum cassia, myrrh, clove, mace nutmeg, Loranthus mulberry mistletoe, rhizoma dioscoreae, ligustrum japonicum, drynaria, fleece-flower root, and black sesame seeds|align = "justify"|Enhances the hair growth and healthier hairs|-|align = "justify"|[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN02111941.4&leixin=fmzl&title=一种含中西药复方的育发剂&ipc=A61K7/06 CN1463693]<br>朱静建 2002|Hair growing preparation containing compound of Chinese medicine and Western medicine<br>一种含中西药复方的育发剂|align = "justify"|Hair matrix activator|Mixture of Herbal extracts and western medicine|align = "justify"|Persimmon leaf, oriental arbor-vitae leaf, ginseng leaf, yellow qi, fruit of the glossy privet, polygonum multiflorum, Kudzu root, dry ginger; Plus：Minoxidil, Vitamins and derivative, cystine, serine, leucine.|align = "justify"|Better and faster hair growth|-|align = "justify"|[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN02155404.8&leixin=fmzl&title=毛囊激活液&ipc=A61K35/78 CN1506103]<br>赵章光2002|align = "justify"|Hair follice activating liquid<br>毛囊激活液|align = "justify"|Vasodilators|align = "justify"|Herbal extract|align = "justify"|Ginseng, twists the stock blue, the licorice, the Sophora flavescens and hot peppers|align = "justify"|Activates the hair-follicle and enhances the hair growth.|-|align = "justify"|[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN01127395.X&leixin=fmzl&title=一种止脱生发药物及其制备方法&ipc=A61K35/78 CN1403100]<br>范希田 2001|align = "justify"|Trichogen and its prepn<br>一种止脱生发药物及其制备方法|align = "justify"|Vasodilators|align = "justify"|Herbal extract|align = "justify"|Ginseng, ganoderma lucidum, Chinese rhubarb, polygonum multiflorum, Chinese prickly ash, ginger, grass seed|align = "justify"|Promote blood circulation and enhance hair growth|-|align = "justify"|[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN96116925.7&leixin=fmzl&title=免洗养发生发香波&ipc=C11D3/48 CN1165181]<br>殷国健 1996|Washing free shampoo for nourishing and growing hair<br>免洗养发生发香波|align = "justify"|Vasodilator|Vitamin composition|align = "justify"|Vitamin P (Bioflavonoids), Vitamin B15, Vitamin B2, nicotinic acid, bromo—geramineum|align = "justify"|Stimulate hair growth|-|align = "justify"|[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN96109964.X&leixin=fmzl&title=一种治疗脂溢性脱发的高效低副作用外用药物&ipc=A61K35/78 CN1150043]<br>梅晓春 1996|Efficient low-side effect external use medicine for curing seborrheic baldness<br>一种治疗脂溢性脱发的高效低副作用外用药物|align = "justify"|Anti-androgen <nowiki>+</nowiki> Vasodilator|Mixture of Herbal extracts and organic compounds|align = "justify"|Polygonum multiflorum, Ligustrum lucidum, Morus alba, Rehmannia glutinosa, Eclipta prostrata, Saliva miltiorrhiza, Carthamus tinctorius, Cnidium monnieri, Sophora flavescens, Dictamnus dasycarpus, Kochia scoparia, and antioxidants|align = "justify"|Inhibit the excess secretion of the sebaceous glands, increase the blood circulation on scalp and enhance the hair growth|-|align = "justify"|[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN88103853.9&leixin=fmzl&title=一种通络生发香波&ipc=A61K7/06 CN1031022]<br>天津市轻工业化学研究所 1988|Channel-stimulating and hair-growing hair shampoo<br>一种通络生发香波|align = "justify"|Vasodilators|Herbal extract <nowiki>+</nowiki> detergent|align = "justify"|<font color="#454545">Herbal extracts, Penetration media, Detergents.</font>|align = "justify"|Increases the blood circulation under the scalp, reduces the hair los|-|}<br clear="all">  ==<span style="color:#C41E3A">Like this report?</span>==<p align="center"> '''This is only a sample report with brief analysis''' <br>'''Dolcera can provide a comprehensive report customized to your needs'''</p>{|border="2" cellspacing="0" cellpadding="4" align="center" "|style="background:lightgrey" align = "center" colspan = "3"|'''[mailto:info@dolcera.com <span style="color:#0047AB">Buy the customized Alopecia report from Dolcera</span>]''' |-| align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]|align = "center"| [http://www.dolcera.com/website_prod/services/business-research-services Market Research Services]|align = "center"| [http://www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard]|-|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services]|align = "center"| [http://www.dolcera.com/website_prod/research-processes Dolcera Processes]|align = "center"| [http://www.dolcera.com/website_prod/industries Industry Focus]|-|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services]|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services]|align = "center"| [http://www.dolcera.com/website_prod/tools Dolcera Tools]|-|}<br>

== Useful links Contact Dolcera==* {| style="border:1px solid #AAA; background:#E9E9E9" align="center"|-! style="background:lightgrey" | Contact Dolcera|-| '''Email''': [httpmailto://www.biocartainfo@dolcera.com/pathfiles/h_ghPathwayinfo@dolcera.asp Pathways examplecom]* [http|-| '''Phone'''://www.cellsignal.com/category.asp?catalog_name=CellSignal&category_name=MAPK+Signaling Signaling Pathways]1-650-269-7952|}